ROSE Diagnostics key facts
- Developer of lymph biomarkers designed for cancer diagnostics.
- It has raised $3.4M across 2 recorded rounds; the latest was Seed Round ($2.3M) in May 2025.
- ROSE Diagnostics has filed 2 Form Ds with the SEC since 2024, most recently May 2025 ($2.3M sold to 18 investors).
- Status: Privately Held (backing).
- ·Watch ROSE Diagnostics: the Monday email on marks, rounds and moves
ROSE Diagnostics funding rounds
2 roundsHow much has ROSE Diagnostics raised?
ROSE Diagnostics has raised $3.4 million across 2 recorded rounds since 2024. The largest was a $2.3 million seed round in May 2025.
ROSE Diagnostics has filed 2 Form Ds with the SEC since 2024, most recently in May 2025 ($2.3 million sold to 18 investors).
About ROSE Diagnostics
Developer of lymph biomarkers designed for cancer diagnostics. The company's product uses a multiplexed dynamic predictive algorithm, sandwiched immunoassay and lateral flow format, among others, enabling medical organizations to provide patients with better treatment options for a wide range of medical conditions.
- Sector
- Healthcare
- HQ
- Carlsbad, CA, United States
- Founded
- 2023
- Employees
- 5
- Website
- rose-dx.com/
- Ownership
- Privately Held (backing)
Is this your company? Profiles are maintained at PrivateMarketView, the data platform behind this page — sign in with your work email to keep it current, or tell us what's wrong.
ROSE Diagnostics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.